Cargando…

Effect of Repeated Intravenous Amantadine Infusions in Patients with Parkinson's Disease: An Open‐Label Pilot Study

Amantadine is an antiviral drug available in oral and intravenous forms. Oral amantadine is used to treat the motor symptoms of early Parkinson's disease (PD) and to ameliorate dyskinesia in late‐stage disease. However, the long‐term influence of intravenous amantadine on motor symptoms and dys...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khlebtovsky, Alexander, Steiner, Israel, Treves, Therese, Djaldetti, Ruth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853147/ https://www.ncbi.nlm.nih.gov/pubmed/31436382 http://dx.doi.org/10.1111/cts.12684

Ejemplares similares

Perspective: Identification of genetic variants associated with dopaminergic compensatory mechanisms in early Parkinson's disease
por: Greenbaum, Lior, et al.
Publicado: (2013)

Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson’s Disease: An Open-Label, Pragmatic Trial
por: Kim, Aryun, et al.
Publicado: (2018)

Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102
por: Isaacson, Stuart H., et al.
Publicado: (2018)

Paraneoplastic Chorea Managed with Intravenous Amantadine
por: Doher, Nicholas, et al.
Publicado: (2019)

Amantadine, COVID-19 and Parkinsonism
por: Wiwanitkit, Viroj
Publicado: (2020)

EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease
por: Tanner, Caroline M., et al.
Publicado: (2020)

Response to: Amantadine, COVID-19 and Parkinsonism
por: Aranda-Abreu, Gonzalo Emiliano
Publicado: (2020)

Amantadine-Induced Patulous Eustachian Tubes in Parkinson's Disease
por: Boyd, J. T., et al.
Publicado: (2013)

Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial
por: Sawada, Hideyuki, et al.
Publicado: (2010)

An updated meta-analysis of amantadine for treating dyskinesia in Parkinson's disease
por: Kong, Min, et al.
Publicado: (2017)

Investigation of the Long-Term Effects of Amantadine Use in Parkinson’s Disease
por: Park, Sangmin, et al.
Publicado: (2023)

A Randomized, Open Label, Exploratory Trial Comparing Efficacy of Amantadine and Ropinirole in Restless Legs Syndrome
por: Madhaw, Govind, et al.
Publicado: (2023)

Amantadine‐Induced Craniofacial Myoclonus: Distinctive Iatrogenic Dysarthria in Parkinson's Disease
por: Lin, Iris, et al.
Publicado: (2023)

Intravenous Ketamine Infusions in Treatment-Resistant Bipolar Depression: An Open-Label Naturalistic Observational Study
por: Wilkowska, Alina, et al.
Publicado: (2021)

Amantadine in Treatment of Dysthymia—The Pilot Case Series Study
por: Krzystanek, Marek, et al.
Publicado: (2023)

Oculometric measures as a tool for assessment of clinical symptoms and severity of Parkinson’s disease
por: Reiner, Johnathan, et al.
Publicado: (2023)

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study
por: Hauser, Robert A., et al.
Publicado: (2017)

Impact of Oral Fast Release Amantadine on Movement Performance in Patients with Parkinson’s Disease
por: Muhlack, Siegfried, et al.
Publicado: (2010)

Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study)
por: Pahwa, Rajesh, et al.
Publicado: (2015)

Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease
por: Sharma, Vibhash D, et al.
Publicado: (2018)

Molecular docking investigation of the amantadine binding to the enzymes upregulated or downregulated in Parkinson’s disease
por: Ionescu, Mihaela Ileana
Publicado: (2020)

An open-label pilot study with high-dose thiamine in Parkinson's disease
por: Costantini, Antonio, et al.
Publicado: (2016)

Anti-CV2/CRMP5 Paraneoplastic Chorea Effectively Managed with Intravenous Amantadine
por: Ha, Jongmok, et al.
Publicado: (2019)

Subcutaneous Levodopa Infusion for Parkinson's Disease: 1‐Year Data from the Open‐Label BeyoND Study
por: Poewe, Werner, et al.
Publicado: (2021)

Neuroprotective effect of Spirulina fusiform and amantadine in the 6-OHDA induced Parkinsonism in rats
por: Chattopadhyaya, I, et al.
Publicado: (2015)

Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson’s disease
por: Hauser, Robert A., et al.
Publicado: (2022)

Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease
por: Fan, Qian-Ya, et al.
Publicado: (2022)

Erratum to: Neuroprotective effect of Spirulina fusiform and amantadine in the 6-OHDA induced Parkinsonism in rats
por: Chattopadhyaya, I., et al.
Publicado: (2015)

Use of amantadine in the evaluation of response to chemotherapy in lung cancer: a pilot study
por: Maksymiuk, Andrew W, et al.
Publicado: (2021)

Safety and tolerability of short‐term infusions of intravenous lacosamide in pediatric patients with epilepsy: An open‐label, phase 2/3 trial
por: Farkas, Mark Kristof, et al.
Publicado: (2023)

Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson’s Disease and Dyskinesia
por: Mehta, Shyamal H., et al.
Publicado: (2021)

Amantadine therapy for Parkinson’s Disease: In Vivo Confocal Microscopy corneal findings, case report and revision of literature
por: Cennamo, Michela, et al.
Publicado: (2022)

Medical Case Report on Repeat Treatment of Restless Legs Syndrome with Intravenous Infusion of Iron
por: Condon, Katherine, et al.
Publicado: (2021)

Amantadine Effect on Perceptions of Irritability after Traumatic Brain Injury: Results of the Amantadine Irritability Multisite Study
por: Hammond, Flora M., et al.
Publicado: (2015)

Massive Intravenous Infusions
por: Harrison, William, et al.
Publicado: (1954)

Continuous Intravenous Infusion
por: Farquharson, Eric L.
Publicado: (1934)

Rotigotine Objectively Improves Sleep in Parkinson's Disease: An Open-Label Pilot Study with Actigraphic Recording
por: Calandra-Buonaura, Giovanna, et al.
Publicado: (2016)

Recombinant Human C1 Esterase Inhibitor for the Management of Adverse Events Related to Intravenous Immunoglobulin Infusion in Patients With Common Variable Immunodeficiency or Polyneuropathy: A Pilot Open-Label Study
por: Melamed, Isaac R., et al.
Publicado: (2021)

Amantadine Treatment for People with COVID-19
por: Araújo, Ramiro, et al.
Publicado: (2020)

Protocol of a randomized open label multicentre trial comparing continuous intrajejunal levodopa infusion with deep brain stimulation in Parkinson’s disease - the INfusion VErsus STimulation (INVEST) study
por: van Poppelen, D., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ndfe74r40qj5n2hf7cqcgt8i24